Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.
about
Interventions for central serous chorioretinopathy: a network meta-analysisInterventions for central serous chorioretinopathy: a network meta-analysisIndocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy.One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot studyTopical nepafenac in treatment of acute central serous chorioretinopathy.Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.Polypoidal choroidal vasculopathy and history of central serous chorioretinopathy.Transpupillary thermotherapy for atypical central serous chorioretinopathy.High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study.The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.Helicobacter pylori infection and eye diseases: a systematic review.Central serous chorioretinopathy: update on pathophysiology and treatment.Factors influencing the visual acuity of chronic central serous chorioretinopathyMorphologic Changes in the Foveal Photoreceptor Layer before and after Laser Treatment in Acute and Chronic Central Serous Chorioretinopathy Documented in Spectral-Domain Optical Coherence Tomography.Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcomeOral Rifampin treatment for longstanding chronic central serous chorioretinopathy.The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy.Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degenerationVariation in Visual Outcome to Anti-Vascular Endothelial Growth Factors in Choroidal Neovascular Membrane Developing in Eyes with Previously Untreated Versus Focal Laser-Treated Central Serous Chorioretinopathy.Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic TherapyLong-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).Association of Choroidal Neovascularization and Central Serous Chorioretinopathy With Optical Coherence Tomography Angiography.Factors affecting the visual outcome in acute central serous chorioretinopathy.Central serous chorioretinopathy: a review of epidemiology and pathophysiology.Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.Circadian disturbance and idiopathic central serous chorioretinopathy.Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy.Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.Changes of outer retinal microstructures after photodynamic therapy for chronic central serous chorioretinopathy.Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy.Role of Avastin in management of central serous chorioretinopathy.Low-dose aspirin as treatment for central serous chorioretinopathyShort-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.
P2860
Q24186996-A96137CA-913D-4701-A533-C4305F67DB2EQ24188115-41AF1A89-F3C2-4213-A37A-6A6DEFCA19A6Q30905661-8BDF5ABD-56E5-42D0-ABF4-F98256625FDFQ31112014-26556E78-AA04-4961-8AA7-40300ADAD9CFQ33195722-3E8638BF-BAD9-4214-A323-97D0EF08E27BQ33239033-15D71BA8-0DF2-42E5-9081-88757E6CBA4FQ33597082-702A8103-F634-4374-B1AE-6DB02FC91CBEQ33705962-ADB97A27-CD1A-4279-99E3-594D1AF931BFQ33899231-C86EAA45-D308-4725-8F06-1081E364D8CDQ33996055-8E34A237-5B32-463C-9218-45C790BD81DDQ34055052-34233EDE-5905-4EF8-9A3B-8D4AE358C7B3Q34158234-8B8E742E-E04C-43A0-AD5F-1315D78EB69DQ34338611-25EAF2C3-04F3-43DA-98B4-A95128E05D88Q34394791-B1FB93B6-A8D2-49DC-B495-08C5751DEAB0Q34454857-B1DFF37F-8390-466D-8515-915D396AD342Q34587658-32EA1723-0F5E-4541-BD3E-E1034C1BF6E6Q34695063-82781811-13D9-4634-AEAF-2A74C37FAE61Q35028601-E7594A49-6F2E-487E-B243-E11000CB2AC3Q35088788-3B031E7C-53C8-4759-80AD-BEB19AB0C1B5Q35582953-8C7C1FDF-697B-4A0C-86B9-BEE41C3CBCA2Q35657257-A9CDD200-EC36-42F8-8876-F1C7017C6C9DQ35782233-2A841171-6443-416C-9AD9-B43B7B63423BQ36050969-2A2F5CA6-193A-483E-8E22-8C592ABD6C1AQ36106039-4FC2335C-D669-4ACA-80C4-B021A518D7FDQ36135515-9F478261-5693-4CEC-B70C-8D06346AD0ADQ36407625-43BFAB30-8120-4C5E-BB04-DD70D0745C55Q36487164-88C29F3B-78EE-47CE-8E1C-4837D3EF5A99Q37723609-121DF24E-DAA5-4C47-9047-D852BC793E4DQ38025702-8A71830A-C317-4ED1-B56D-44182CAD4F8CQ38644045-07782603-B26A-485D-881C-0CF07B566DDAQ38701151-5942DD35-3297-471E-9906-BB3268B8AB1CQ39127843-5C185F73-D926-4734-AADA-86D2DE6D1312Q40516288-53A826C3-8850-4AE9-9C97-8A5184F7FD68Q41190093-41B5EECD-6C6F-4722-A273-4084575644DCQ41362947-7482163E-8CA5-409E-AB2A-CD33B463D591Q41484477-CF6141C2-F61C-4E97-ACCD-12F14B60CE30Q41746219-55AF6B06-6B84-4C45-A542-CE424DC257F0Q41774757-59D8A198-8A21-406F-AD3E-0CD37F683F7CQ41899388-05E8622E-7529-4808-87B7-57CEED6C2173Q42153332-7FC16062-0609-4CED-A18D-BA0095DA6503
P2860
Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Factors associated with reduce ...... tral serous chorioretinopathy.
@ast
Factors associated with reduce ...... tral serous chorioretinopathy.
@en
type
label
Factors associated with reduce ...... tral serous chorioretinopathy.
@ast
Factors associated with reduce ...... tral serous chorioretinopathy.
@en
prefLabel
Factors associated with reduce ...... tral serous chorioretinopathy.
@ast
Factors associated with reduce ...... tral serous chorioretinopathy.
@en
P2093
P1433
P1476
Factors associated with reduce ...... tral serous chorioretinopathy.
@en
P2093
Harry W Flynn
Ingrid U Scott
J Donald M Gass
Mary Lou Lewis
Phillip J Rosenfeld
Timothy G Murray
William E Smiddy
P356
10.1097/00006982-200202000-00004
P577
2002-02-01T00:00:00Z